<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100504">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796171</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2011-000033-36</org_study_id>
    <nct_id>NCT01796171</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma</brief_title>
  <acronym>LYMRIT-37-01</acronym>
  <official_title>A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Nanovector</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Nanovector</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I/II, open-label study in patients with relapsed positive non-Hodgkin
      lymphoma. The Phase I part of the study is a dose escalating study to define the maximum
      tolerable dose of 177Lu-DOTA-HH1 (Betalutin), assess safety and toxicity, pharmacokinetics,
      biodistribution and efficacy. After completion of the phase I study, a dose will be selected
      for the phase II part of the study which is designed to investigate tumour response rate,
      progression free survival, confirmation of the selected dose as well as safety and toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/Dose limiting toxicity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients are closely monitored during and after injection of Betalutin over a 12 week period. Thereafter, at certain intervals up to 5 years. Safety evaluations are vital signs, physical examination, hematology and serum biochemistry.
Adverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 months - 5 years</time_frame>
    <description>CT or PET/CT imaging will be used to quantify changes in lesions on baseline imaging, with responses classified according to revised response criteria for NHL (Cheson, 2007.)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>With HH1 pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 10 MBq/kg b.w. in escalated doses with HH1 pre-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With rituximab pre-dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Different HH1 pre-dosing regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin, 15 MBq/kg b.w. in escalated doses with a different HH1 pre-dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Dose finding study, starting on 10 MBq/kg b.w. Betalutin (177Lu-Dota-HH1), single injection.</description>
    <arm_group_label>With HH1 pre-dosing</arm_group_label>
    <arm_group_label>Without pre-dosing</arm_group_label>
    <arm_group_label>With rituximab pre-dosing</arm_group_label>
    <arm_group_label>Different HH1 pre-dosing regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed (by WHO classification) relapsed incurable non-Hodgkin
             B-cell lymphoma of following subtypes; follicular grade I-IIIA, marginal zone, small
             lymphocytic, lymphoplasmacytic, mantle cell.

          2. Age ≥ 18 years

          3. A pre-study WHO performance status of 0-1

          4. Life expectancy should be ≥ 3 months

          5. &lt;25% tumour cells in bone marrow biopsy

          6. Measurable disease by radiological methods

          7. Women of childbearing potential must:

               1. understand that the study medication is expected to have teratogenic risk

               2. have a negative pregnancy test

               3. agree to use, and be able to comply with, effective contraception without
                  interruption, 4 weeks before starting study drug, throughout study drug therapy
                  and for 12 months after end of study drug therapy, even if she has amenorrhoea

          8. Male subjects must agree to use condoms during intercourse throughout study drug
             therapy and the following 12 months

          9. Patients previously treated with native rituximab are eligible

         10. The patient is willing and able to comply with the protocol, and agrees to return to
             the hospital for follow-up visits and examination

         11. The patient has been fully informed about the study and has signed the informed
             consent form

        Exclusion Criteria:

          1. Medical contraindications, including uncontrolled infection, severe cardiac,
             pulmonary, neurologic, psychiatric or metabolic disease, steroid requiring
             asthma/allergy, known HIV positive

          2. Laboratory values within 15 days pre-registration:

               1. Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l

               2. Platelet count ≤ 150 x 109 /l

               3. Total bilirubin ≥ 30 mmol/l

               4. ALP and ALAT ≥ 4x normal level)

               5. Creatinine ≥ 115 µmol/l (men), 97 µmol/l (women))

               6. IgG ≤ 3 gr/l

          3. Known CNS involvement of lymphoma

          4. Previous total body irradiation, or irradiation of &gt; 25% of the patient's bone marrow

          5. Known history of HAMA

          6. Chemotherapy or immunotherapy received within the last 4 weeks prior to start of
             study treatment. Pretreatment with rituximab is allowed

          7. Pregnant or lactating women

          8. Previous hematopoietic stem cell transplantation (autologous and allogenic)

          9. Previous treatment with radioimmunotherapy

         10. Actively participating in another study or received an investigational drug within 4
             weeks prior to enrolment

         11. Receipt of live, attenuated vaccine within 30 days prior to enrolment

         12. Test positive for hepatitis B (HBsAg and anti-HBc)

         13. A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any
             excipient used in rituximab, HH1 or Betalutin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arne Kolstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Baylor Curtis</last_name>
    <phone>+44 7557806472</phone>
    <email>lbaylorcurtis@nordicnanovector.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>12 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>50-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Borås</city>
        <zip>50455</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95.</citation>
    <PMID>23267131</PMID>
  </reference>
  <reference>
    <citation>Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7.</citation>
    <PMID>23256748</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 20, 2016</lastchanged_date>
  <firstreceived_date>February 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radioimmunotherapy</keyword>
  <keyword>Lu-177</keyword>
  <keyword>Phase I study</keyword>
  <keyword>Phase II study</keyword>
  <keyword>Betalutin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
